Japan Based Eisai News Today

Biogen's Leqembi, the first drug to slow the progression of Alzheimer's, launched last year

Patients in the UK must undergo a swathe of tests, including scans and a lumbar puncture, with some facing waits of up to four years for their Alzheimers diagnosis.

The FDA approved Leqembi for people with early Alzheimer's disease on Thursday, making it easier for older adults to obtain the first drug to slow memory and thinking issues.

Eisai and Biogens drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDAs full review.

Eisai and Biogens drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDAs full review.

The U.S. Food and Drug Administration has granted full approval of an Alzheimer’s drug that many hope will help slow the disease.

Eisai and Biogens drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDAs full review.

Eisai and Biogens drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDAs full review.

Eisai and Biogens drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDAs full review.

Eisai and Biogens drug, sold under the brand name Leqembi, is the first amyloid-targeting medication to pass the FDAs full review.